The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species

The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species

Brensocatib is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which activates several neutrophil serine proteases (NSPs), including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in the bone marrow during the early stage of neutrophil maturatio...

Full description

Bibliographic Details
Main Authors: Jessica Basso, Kuan-Ju Chen, Yuchen Zhou, Lilly Mark, Daniel LaSala, Arielle Dorfman, Mary Atalla, Donald Chun, Veronica Viramontes, Christina Chang, Franziska Leifer, Patrick P. McDonald, David C. Cipolla
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Pharmacology
Subjects:
neutrophil elastase (NE)
proteinase 3 (PR3)
cathepsin G (CatG)
cathepsin C (CatC)
dipeptidyl peptidase 1 (DPP1)
brensocatib
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1208780/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1208780/full

Similar Items